

July 30, 2024

To,

BSE Limited
Listing Department-
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001
Dear Sir/ Madam,

Subject: **Intimation of Press Release as per SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

Enclosing is the press release to be made by the Company w.r.t Technology Collaboration Agreement to be entered into by the Company with Bhami's Research Laboratory Private Limited.

The above information is also available on the website of the Company i.e. <https://www.stelis.com/corporate-governance/>. You are requested to kindly take the same on record.

Thanking you,

For and on behalf of
OneSource Specialty Pharma Limited

A TRISHA
Digitally signed by A
TRISHA
Date: 2024.07.30 11:43:09
+05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli
Bannerghatta Road, Bangalore – 560076, India
Tel: +91 80 6784 0000

E: CS@onesourcecdmo.com | W: www.stelis.com

CIN: U74140KA2007PLC043095

Press Release

OneSource and Bhami's Research Laboratory entered into Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously

Revolutionary technology will further boost OneSource's scientific services offerings

Bangalore, India, 30th July, 2024 – OneSource Specialty Pharma Limited, associate company of Strides and India's first specialty pharma pure-play CDMO (Contract Development and Manufacturing Organization) has entered into a strategic licensing agreement with Bhami's Research Laboratory (BRL). This partnership will provide OneSource with access to BRL's HILOPRO® formulation technology, enabling the subcutaneous delivery of high-concentration biologic therapies. This innovative technology aims to reduce viscosity and facilitate the delivery of high-concentration biologic products, applicable across a broad spectrum of monoclonal antibodies and fusion proteins. Under the agreement, OneSource will offer BRL's innovative formulation technology, enhancing its development and manufacturing services for both drug products and substances.

OneSource offers world-class capabilities across biologics, complex injectables and drug-device combination products, soft gelatin capsules and has demonstrated experience on different therapeutic modalities and technology platforms. With five state-of-the-art cGMP facilities and a global customer base, OneSource has an impeccable quality compliance record with successful inspections by major health agencies, including the USFDA and EU authorities.

Commenting on the development Neeraj Sharma, Managing Director, OneSource said *"We are excited to partner with Bhami's Research Laboratory, marking a significant step forward for OneSource in enhancing the subcutaneous delivery of high-concentration biologic therapies. This collaboration underscores our commitment to leveraging innovative technologies to address critical challenges in biopharmaceutical development. BRL's formulation technology offers promising capabilities to reduce viscosity and enable effective delivery of a wide spectrum of biologic products. The adoption of subcutaneous delivery for small-volume, low-viscosity biotherapeutics offers substantial benefits to patients compared to traditional intravenous injections, including improved healthcare accessibility, reduced hospitalization requirements, lower overall treatment costs. This technology platform also complements our strong and demonstrated experience in biologics drug substance and drug delivery devices (such as auto-injectors and pens). We are looking forward to offering this technology to our existing and prospective customers, across innovative biologic and biosimilar products".*

Commenting on the partnership Dr. Surya Pai, Co-founder and Chief Executive Officer of BRL said *"We are pleased to announce our collaboration with OneSource, a distinguished specialty pharma pure-play CDMO, to expand the accessibility of our advanced subcutaneous protein delivery platform. This partnership represents a significant advancement in our commitment to enhancing biologic therapy delivery. Our globally patented high-concentration, low-viscosity protein drug delivery platform aims to optimize patient care by offering convenient, affordable, and safe treatment options. Together with OneSource, we look forward to setting new benchmarks in biopharmaceutical innovation and improving healthcare outcomes worldwide."*

About OneSource Specialty Pharma

OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is India’s first specialty pharma pure-play CDMO business. By integrating Stelis’ Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, we are positioned to deliver exceptional services to our customers. Following the NCLT process and listing, OneSource Specialty Pharma will operate five state-of-the-art facilities in Bengaluru, India, all approved by major regulatory bodies, including the USFDA and EU authorities. Along with a team of over 1,200 professionals, including 200+ techno-commercial experts, we specialize in diverse dosage formats and advanced biologics platforms.

Our comprehensive solutions span across platforms and therapeutic modalities, including Biologics, Drug-device combinations, Complex Injectables, and Oral Technologies. Committed to innovation and excellence, we support global partners in delivering life-saving products efficiently.

For more information, visit www.stelis.com.

About Bhami’s Research Laboratory (BRL)

Bhami’s Research Laboratory Pvt. Ltd. (BRL) is a ten-year-old biotech company based out of India, with core expertise in protein and oral peptide drug delivery. BRL aims to enhance the delivery of biologics therapeutics through its proprietary high-concentration subcutaneous protein delivery technology. Additionally, BRL also focuses on oral delivery of peptides through its novel proprietary technology.

For more information, www.bhamilab.com.

Media Contact:

<p><u>Corporate Communication</u></p> <p>Pallavi Panchmatia: +91 8951939181 / Abhilash Mukherjee: +91 8904428907 Email: corpcomm@stelis.com</p>	<p><u>PR Consultancy</u></p> <p>Adfactors PR Janhavi Bellare: +91 93228 54508 Email: Janhavi.bellare@adfactorspr.com Talal Syed: +91 99876 19679 Email: syed.talal@adfactorspr.com</p>
---	--

**Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulation, 2015**

Any of the following events pertaining to the listed entity

#	Particulars	Remarks
1)	Arrangements for Strategic, Technical, Manufacturing, or Marketing tie-up:	
	a) Agreement/ Joint Venture (JV) with companies:	
	i. Name of Entity(ies) with whom Agreement/ JV is signed;	Bhami's Research Laboratory Private Limited
	ii. Area of Agreement/ JV;	Technology Collaboration Agreement
	iii. Domestic/ International;	Partner is based / located in India, but the technology has usage internationally
	iv. Share Exchange Ratio/ JV ratio;	NA
	v. Scope of Business Operation of Agreement/ JV;	Pharmaceutical formulation development
	vi. Details of consideration paid/ received in agreement / JV;	NIL
	vii. Significant Terms and Conditions of agreement/ JV in brief;	Access to proprietary technology platform
	viii. Whether acquisition would fall within Related Party Transactions and Whether Promoter/ Promoter Group/ Group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms' length";	No
	ix. size of the entity(ies);	Less than 50 People
	x. rationale and benefit expected	Providing One stop solution to our customers via enhanced formulation offering
	b) In event that any such arrangement is called off for any reason, the same shall be disclosed along with the reasons for calling off the proposal.	Yes

2)	Adoption of new line(s) of business:	NA
	a) industry or area to which the new line of business belongs to;	
	b) expected benefits;	
	c) estimated amount to be invested	
3)	Closure of operations of any unit/division - (entirety or piecemeal):	NA
	a) Date of such binding agreement, if any, entered for sale of such unit/ division, if any;	
	b) Amount & percentage of Turnover or Revenue or Income and Net worth of Listed Entity contributed by such unit or division during the last financial year;	
	c) Date of closure or estimated time of closure;	
	d) Reasons for closure.	
